A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Bladder | Brain and Nervous System | Breast - Female | Cervix Uteri | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Multiple Myeloma | Non-Hodgkin's Lymphoma | Other Female Genital | Other Male Genital | Pancreas | Prostate | Rectum | Soft Tissue | Stomach | Thyroid
What is the purpose of this trial?
- To evaluate the safety and tolerability of MPDL3280A administered by intravenous (IV) infusion every 3 weeks (q3w) to patients with locally advanced or metastatic solid tumors
- To determine the maximum tolerated dose (MTD) and to evaluate the dose-limiting toxicities (DLTs) of MPDL3280A when administered as a single agent to patients by IV infusion q3w
- To identify a recommended Phase II dose of MPDL3280A
- 18 Years and older
Click here for detailed information about who can participate in this trial.
- Genentech, Inc.
- Last Updated:
- Study HIC#: